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Existing licensed anthrax vaccines are administered parenterally and require multiple doses to induce
protective immunity. This requires trained personnel and is not the optimum route for stimulating a mucosal
immune response. Microencapsulation of vaccine antigens offers a number of advantages over traditional
vaccine formulations, including stability without refrigeration and the potential for utilizing less invasive
routes of administration. Recombinant protective antigen (rPA), the dominant antigen for protection against
anthrax infection, was encapsulated in poly-L-lactide 100-kDa microspheres. Alternatively, rPA was loosely
attached to the surfaces of microspheres by lyophilization. All of the microspheric formulations were admin-
istered to A/J mice with a two-dose schedule by either the intramuscular route, the intranasal route, or a
combination of these two routes, and immunogenicity and protective efficacy were assessed. An intramuscular
priming immunization followed by either an intramuscular or intranasal boost gave optimum anti-rPA
immunoglobulin G titers. Despite differences in rPA-specific antibody titers, all immunized mice survived an
injected challenge consisting of 103 median lethal doses of Bacillus anthracis STI spores. Immunization with
microencapsulated and microsphere-associated formulations of rPA also protected against aerosol challenge
with 30 median lethal doses of STI spores. These results show that rPA can be encapsulated and surface bound
to polymeric microspheres without impairing its immunogenicity and also that mucosal or parenteral admin-
istration of microspheric formulations of rPA efficiently protects mice against both injected and aerosol
challenges with B. anthracis spores. Microspheric formulations of rPA could represent the next generation of
anthrax vaccines, which could require fewer doses because they are more potent, are less reactogenic than
currently available human anthrax vaccines, and could be self-administered without injection.
Anthrax, the disease caused by the spore-forming bacterium
Bacillus anthracis, occurs in three distinct forms, cutaneous,
gastrointestinal, and pulmonary, depending upon the route of
infection. Cutaneous anthrax, in which the spores infect a le-
sion in the skin, produces a characteristic black eschar and
edema at the site of infection and can be effectively treated
with antibiotics. Gastrointestinal and pulmonary anthrax infec-
tions, caused by ingestion and inhalation of spores, respec-
tively, are more difficult to diagnose and treat successfully as
the symptoms of infection are not always apparent in time for
antibiotic treatment to be effective (21), so vaccination is es-
sential to protect individuals who are likely to be exposed.
There are currently two licensed anthrax vaccines available for
human use. The current United Kingdom-licensed anthrax
vaccine is an alum-precipitated filtrate of a B. anthracis Sterne
strain culture which is administered by the intramuscular (i.m.)
route and occasionally causes some transient reactogenicity. It
also has a limited duration of protection, requiring frequent
boosting for continued immunity, and there is some uncer-
tainty concerning its protective efficacy against inhaled spores
of the more virulent strains of B. anthracis (17). The second
vaccine, licensed for use in the United States, is AVA (anthrax
vaccine adsorbed), which consists mainly of protective antigen
(PA) from cultures of the unencapsulated, toxin-producing
strain B. anthracis V770-NP1-R adsorbed onto aluminum hy-
droxide (12). This vaccine is administered by the subcutaneous
route and has similar disadvantages; it causes occasional minor
reactions at the injection site and requires annual boosting to
maintain immunity (5), although it provides protection against
inhalational anthrax in rhesus macaques (4, 12).
B. anthracis produces two virulence factors, a poly-D-glu-
tamic acid capsule (8) and a tripartite toxin composed of PA
plus either lethal factor or edema factor, resulting in lethal
toxin or edema toxin (18). PA is the key component in existing
vaccines that protect against anthrax infection. It is an 83-kDa
protein, and when it binds to the host cell membrane receptor,
it is cleaved and releases a 20-kDa fragment, which exposes the
lethal factor-edema factor binding site (14). The resulting 63-
kDa protein forms a heptameric pore, the lethal factor or
edema factor binds, and the toxin complex is internalized by
receptor-mediated endocytosis (6, 20). Therefore, it is clear
that inhibition of PA binding to the host cell surface should be
a strategy for protection against anthrax infection.
Antibodies to PA are essential for immunity to anthrax in-
fection (22). To protect individuals from pulmonary anthrax
infection, the immune effector mechanisms at the lung surface
and in the respiratory tract may also need to be primed. This
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can be achieved by targeting future vaccines to the mucosal
immune system. Intranasal (i.n.) immunization is particularly
effective at inducing mucosal immunity in the lung (2). Nasal
immunization with recombinant PA (rPA) could be facilitated
by encapsulation of the protein in polymeric microspheres.
This has several advantages compared with more traditional
vaccine formulations: it protects the protein from protease
degradation; it allows sustained release of the protein in the
vaccine, thus reducing the need for frequent boosting; and by
making the protein a particulate antigen, it maximizes the
immunogenicity of the protein.
In the present study, we investigated the optimum format for
presentation of rPA in the context of a microsphere-based
formulation. The immunogenicities of formulations were as-
sessed following i.m. and i.n. administration in a two-dose
immunization regimen, and the subsequent protective effica-
cies against both injected and aerosol challenges with anthrax
STI spores in the A/J mouse model were determined.
MATERIALS AND METHODS
PA. All of the PA used in this study was rPA expressed from Bacillus subtilis
and purified as previously described (19). Briefly, rPA was purified by ammonium
sulfate fractionation of the culture supernatant, followed by ion exchange using
DEAE streamline (Pharmacia), a second ion exchange using a Mono Q HR
10/10 column (Pharmacia), and finally gel filtration using a Sepharose 12 HR
10/30 column. The purified protein was determined to be more than 90% pure
by scanning densitometry.
Microencapsulation of rPA. rPA was entrapped in polymeric microparticles
composed of poly-L-lactide (PLLA) (molecular mass, 100 kDa) by using a double
emulsion solvent evaporation process. Briefly, lyophilized rPA was dissolved in
0.5 ml of an aqueous solution of 2.5% (wt/vol) polyvinyl alcohol (13 to 23 kDa;
88% hydrolyzed; Aldrich, Dorset, United Kingdom). This primary aqueous
phase was vigorously mixed, using a Silverson homogenizer (Silverson Machines,
Bucks, United Kingdom), with an oily phase consisting of 0.25 g of PLLA
(Polysciences, Warrington, Pa.) dissolved in 5 ml of methylene chloride
(CH2Cl2). The resultant water-in-oil emulsion was then added, during vigorous
agitation, to 75 ml of 5% (wt/vol) polyvinyl alcohol (13 to 23 kDa; 88% hydro-
lyzed). Following solvent evaporation overnight, hardened polymeric micropar-
ticles were harvested by centrifugation prior to lyophilization. Microspheres were
characterized with respect to rPA loading, morphology, and size. Bicinchoninic
acid assay (Pierce, Rockford, Ill.) analysis of 1 M NaOH-digested particles was
used to ascertain the loading of rPA. Scanning electron microscopy (Cambridge
Instruments, Cambs, United Kingdom) and laser diffraction measurements
(Malvern Instruments, Worcs, United Kingdom) were used to investigate micro-
sphere size and morphology. The rPA loading of the microspheres was 2.629%
 0.100% (wt/wt) (entrapment efficiency, 90%). The mean particle size was 9.5
 6.8 m (volume mean) or 2.46  1.53 m (number mean). The morphology
of the rPA-containing microspheres is shown in Fig. 1.
Surface modification of rPA-containing and empty microspheres. We at-
tempted to surface modify the antigen-containing PLLA microspheres and
empty PLLA particles (prepared as described above but without rPA in the
formulation) by associating additional quantities of rPA; 50-mg portions of
particles were incubated (at the ambient temperature for 120 min with end-to-
end shaking) in 5 ml of a 0.9% (wt/vol) solution of NaCl containing 300 g of
rPA per ml. The particles were then treated in one of two ways: (i) they were
freeze-dried as a suspension in 5 ml of incubation medium (0.9% [wt/vol] NaCl
solution containing 300 g of rPA per ml) so that the antigen was freeze-dried
onto the particles, or (ii) they were centrifuged at 21,000 rpm (Beckman J2-2
centrifuge) for 30 min, harvested, and washed three times prior to freeze-drying
following suspension in 5 ml of a fresh 0.9% (wt/vol) NaCl solution. The total
amounts of rPA associated (entrapped or adsorbed) with the different formula-
tions were determined by performing a bicinchoninic acid analysis (Table 1).
Animals. Female 6-week-old A/J (Harlan Olac) and BALB/c (Charles River)
mice were used in this study. All mice were supplied as specific-pathogen-free
animals, and a microchip was embedded in each animal to aid identification. This
study was carried out in strict accordance with the Animals (Scientific Proce-
dures) Act 1986.
Immunization and challenge studies. (i) Mucosal immune response to free
rPA. To assess the immunogenicity of rPA when it was administered i.n., each
mouse in groups of five BALB/c mice was given a 5-, 10-, or 20-g dose of rPA
either alone or with 10 g of cholera toxin B subunit (CTB) (Sigma Chemical
Co., Dorset, United Kingdom) in 50 l of phosphate-buffered saline (PBS). The
FIG. 1. Morphology of rPA-containing PLLA microspheres, as viewed by scanning electron microscopy.
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dose was administered as a mixed protein solution to the lightly anesthetized
mouse (inhalational halothane) by direct instillation into the nares. After re-
moval from the anesthetic gas, the mice revived almost immediately. The mice
were immunized on days 1 and 28, and prior to booster immunization, blood
samples were obtained on days 28 and 70.
(ii) Preliminary immunogenicity and protective efficacy of microencapsulated
rPA. To assess the immunogenicity and protective efficacy of a microencapsu-
lated formulation of rPA, groups of six female A/J mice were immunized par-
enterally with either microencapsulated (formulation 5 [Table 1]) or free rPA or
the current United Kingdom anthrax vaccine licensed for use in humans (Centre
for Applied Microbiology and Research, Wiltshire, United Kingdom). The mice
received 0.4 mg of microspheres, which delivered a 10-g dose of rPA, 10 g of
free rPA in 100 l (total volume) of PBS (Oxoid, Basingstoke, United Kingdom),
or 100 l of human anthrax vaccine, which was equivalent to one-fifth of a human
dose. All three formulations were injected i.m. by using a three-dose schedule
that included boost doses of the microencapsulated and free rPA formulations
given 28 and 63 days after the primary immunization and boost doses of the
human anthrax vaccine given on days 28 and 42 after the primary immunization.
Blood samples were taken on days 42 (prior to the boost immunization) and 84
and used for anti-PA immunoglobulin G (IgG) titer analysis performed with an
enzyme-linked immunosorbent assay (ELISA), and the mice were challenged by
the intraperitoneal (i.p.) route on day 105 after the primary immunization with
1  106 anthrax strain STI spores, as described below.
(iii) Screening of surface-modified microspheres for immunogenicity. In order
to enhance the immunogenicity of microencapsulated rPA formulations and
therefore reduce the number of doses required to induce a protective immune
response, the microspheres were modified by attaching rPA to the sphere surface
either by adsorption or lyophilization, as described above. Female BALB/c mice
were immunized i.m. with formulations 1 to 6 (but not formulations 2a and 4a)
(Table 1). Five mice were immunized per treatment group. Each mouse received
10 g of rPA in the encapsulated formulation in 100 l of PBS on days 1 and 21,
and mice immunized with either formulation 1 or formulation 3 received an
additional 10-g i.m. dose on day 111 after the primary immunization. The
immunizing dose for each animal was divided equally between sites on the hind
legs. Blood samples were taken on days 28, 42, 85, and 120 after the primary
immunization.
(iv) Protective efficacy of microencapsulated rPA. The two most immunogenic
formulations, formulations 2 and 4 (see above), were used for experiments to
assess the protection against challenge provided and to ascertain if the immuni-
zation route used increased or decreased the protective efficacy. In this and
subsequent experiments, female A/J mice were immunized since these mice
provide a consistent mouse model for anthrax infection (24). A/J mice were
immunized in groups of 10 by either the i.m. route or the i.n. route or by a
combination of the two (i.m. primary immunization followed by i.n. boost im-
munization or vice versa) with the two formulations. Immunization by the i.m.
route was carried out as described above. For i.n. immunization, sufficient mi-
crospheres to deliver a 10-g dose of rPA per animal were suspended in 50 l of
PBS and administered to a lightly anesthetized mouse as described above. The
animals were primed on day 1 and boosted on day 21. Antibody titers were
monitored by taking blood samples on day 28, and the serum was separated and
used for analysis by ELISA. Mice were challenged with STI spores by the i.p.
route on day 55 of the immunization regimen, as described below.
In a separate experiment, A/J mice (six mice per treatment group) were
immunized by using an identical regimen and either the i.m. route, the i.n. route,
or a combination of the two routes with second batches of formulations 2 and 4
(formulations 2a and 4a, respectively) that were produced with a greater load of
rPA per sphere (Table 1). Each mouse was immunized on days 1 and 21 with
sufficient spheres to deliver a 10-g dose of rPA, and blood samples were taken
on days 28 and 45 and used for serum analysis by ELISA. The mice were
challenged by the aerosol route with STI spores on day 90 of the immunization
regimen.
Injected challenge. For preparation of the challenge inoculum, STI spores
were removed from a stock preparation, washed in sterile distilled water, and
resuspended in PBS at a concentration of 7  108 spores per ml. Aliquots of the
spore suspension were removed, and 100-l portions were used to challenge
mice i.p. with 7  107 spores per mouse (equivalent to 104 median lethal doses
[MLDs] [1]). The spore suspension was diluted and used to challenge immunized
mice with 7  106 spores per mouse (equivalent to 103 MLDs [1]). The animals
were monitored for 14 days after challenge to determine their protected status.
Humane end points were strictly observed so that any animal displaying a col-
lection of clinical signs which together indicated that it had a lethal infection was
culled.
Aerosol challenge. Aerosol exposure was carried out by using a Henderson-
type apparatus (11) and Collison spray (15). Ten-milliliter aliquots of STI spores
were suspended in sterile distilled water at a concentration of 109 CFU ml1, and
3 drops of Antifoam 289 (Sigma) was added just before each preparation was
placed in the Collison spray. Mice were placed in groups of up to 20, and only
their heads were exposed for 10 min to an airstream containing an aerosol of B.
anthracis STI spores generated by the Collison spray and conditioned by the
Henderson-type apparatus. The concentration of STI spores in the aerosol was
determined by taking samples from the exposure chamber with an All-glass
impinger (AGI-30) (16) containing sterile distilled water. Diluted impinger sam-
ples were plated onto nutrient agar to determine the number of spores per liter
of aerosol. The respiratory volume of the animals was calculated by the method
of Guyton (9), and the actual dose inhaled and retained in the lungs was
calculated by using the data of Harper and Morton (10). Animals were closely
observed for 22 days after challenge to determine their protected status.
ELISA of serum samples to determine antibody titer to rPA. Microtiter plates
(Immulon 2; Dynex Technologies) were coated overnight at 4°C with 5 g of rPA
(expressed from B. subtilis [19]) per ml in PBS, except for two rows per plate
which were coated with 5 g of goat anti-mouse antibody binding fragment
(FAb) (Sigma) per ml. The plates were washed with PBS containing 1% (vol/vol)
Tween 20 and blocked with 5% (wt/vol) skimmed milk powder in PBS (blotto)
for 2 h at 37°C. Individual serum samples, double diluted in 1% blotto, were
added to the rPA-coated wells and were assayed in duplicate alongside a murine
IgG standard (Sigma) added to the anti-FAb-coated wells and incubated over-
night at 4°C. After washing, horseradish peroxidase-conjugated goat anti-mouse
IgG, IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotechnology Associates Inc.) was
added to all wells, diluted 1:2,000 in PBS, and incubated for 1 h at 37°C. The
plates were washed again before addition of the substrate 2,2-azinobis(3-ethyl-
benzthiazoline-sulfonic acid) (ABTS) (1.09 mM; Sigma). After 20 min of incu-
bation at room temperature, the absorbance at 414 nm was determined for each
well (Titertek Multiscan; ICN Flow). Standard curves were calculated by using
Titersoft software, version 3.1c. Titers were expressed either in micrograms of
IgG per milliliter of serum or as the reciprocal of the end point dilution which
gave an absorbance that was 0.1 U greater than the background value. Group
means  standard errors of the means were calculated.
Statistical analysis. The significance of the differences in anti-rPA IgG con-
centrations for each administration route for formulations 2, 2a, 4, and 4a was
determined by analysis of variance followed by a t test suitable for multiple
comparisons (7).
RESULTS
Evaluation of the immunogenicity of microencapsulated
rPA compared to that of free rPA and that of the human
TABLE 1. Adsorbtion of rPA onto empty and loaded 100-kDa PLLA microspheres
Formulation Microsphere type Modification Location of rPA Overall loading (%, wt/wt)
1 rPA-containing spheres Adsorb rPA Encapsulated and adsorbed 1.501 0.094
2 rPA-containing spheres rPA weakly attached by lyophilization Encapsulated and weakly bound 3.485 0.095
2a rPA-containing spheres rPA weakly attached by lyophilization Encapsulated and weakly bound 6.812 0.507
3 Empty spheres rPA adsorbed Adsorbed 0.792 0.122
4 Empty spheres rPA weakly attached by lyophilization Weakly bound 2.160 0.160
4a Empty spheres rPA weakly attached by lyophilization Weakly bound 4.957 0.371
5 rPA-containing spheres None Encapsulated 2.629 0.100
6 Empty spheres None NA 0
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anthrax vaccine. Free rPA administered i.n. was nonimmuno-
genic and produced no detectable antibody response to rPA
even at the highest dose (20 g per mouse). In comparison,
when rPA was administered with the potent mucosal adjuvant
CTB, anti-rPA titers of 4.56  0.31, 4.74  0.11, and 4.92 
0.12 for the mice immunized with 5, 10, and 20 g of rPA,
respectively, were produced (titers expressed as mean log10
reciprocal of the dilution standard error of the mean). When
administered by the i.m. route, rPA, either microencapsulated
or free, was immunogenic and stimulated a protective immune
response, and all immunized animals were protected against
i.p. challenge with 1  106 STI spores per mouse (Table 2).
This showed that microencapsulating rPA did not impair its
immunogenicity or protective efficacy and that it was as pro-
tective as the current human anthrax vaccine.
Selection of the optimal formulation of microencapsulated
rPA. All the formulations screened except formulation 6 (emp-
ty spheres) were able to induce antibody to rPA. Formulations
1 (rPA encapsulated and adsorbed) and 3 (adsorbed rPA) were
far less immunogenic and required three immunizing doses to
achieve antibody titers similar to those obtained after two
doses of formulations 2 (spheres with encapsulated and weakly
bound rPA) and 4 (empty spheres with rPA weakly bound)
(Table 3). Formulations 2 and 4 were found to be optimally
immunogenic in the initial screening study and were used for
further evaluation. When trials were performed with A/J mice,
both of these formulations and the subsequently produced
second batches of these formulations (formulations 2a and 4a)
were able to induce substantial anti-rPA IgG titers (Fig. 2). For
each formulation, significantly higher anti-rPA antibody re-
sponses were obtained with two i.m. immunizing doses than
with either two i.n. immunizing doses (formulation 2, P 0.02;
formulation 4, P  0.01; formulation 2a, P  0.001; formula-
tion 4a, P 0.007) or a combination of i.n. priming followed by
i.m. boosting (formulation 2, P  0.07; formulation 4, P 
0.001; formulation 2a, P  0.002; formulation 4a, P  0.02).
There was no significant difference between the anti-rPA IgG
titers for groups immunized with formulation 2 and the anti-
rPA IgG titers for groups immunized with formulation 4 for
any combination of administration routes except for the group
primed with formulation 2 by the i.m. route and then boosted
with an i.n. dose (P  0.013). In contrast, immunization with
formulation 4a by any combination of administration routes
except i.n. priming and boosting resulted in anti-rPA IgG titers
considerably higher than the anti-rPA IgG titers for groups
immunized by the same routes with formulation 2a (two i.m.
doses, P  0.01; two i.n. doses, P  0.08; i.m. priming followed
by i.n. boosting, P  0.055; i.n. priming followed by i.m. boost-
ing, P  0.004). A comparison of the anti-rPA titers after
immunization with formulations 2 and 2a and with formula-
tions 4 and 4a by each combination of immunization routes
showed that there was no significant difference in the titers
stimulated by formulations 2 and 2a except when the formu-
lations were administered i.m. followed by i.n. boosting (P 
0.04), whereas the titers for mice immunized with formulation
4a were considerably higher than the titers for mice immunized
with formulation 4 (two i.m. doses, P  0.02; i.m. priming
followed by i.n. boosting, P 0.05; i.n. priming followed by i.m.
boosting, P  0.001) except for the mice primed and boosted
i.n., for which there was no significant difference in the anti-
rPA IgG responses to the two formulations. The predominant
subclass of IgG seen in samples taken from mice immunized
with either formulation 2a or 4a was IgG1; there were much
lower amounts of IgG2a and IgG2b and no detectable IgG3
(data not shown), indicating that there was a predominantly
Th2-directed response to immunization with these formula-
tions.
Assessment of the protective efficacy of microencapsulated
formulations of rPA. All mice immunized with either formu-
lation 2 or formulation 4 were fully protected against i.p. chal-
lenge with 7  106 STI spores (approximately 103 MLDs). At
a 1-log-higher challenge level (104 MLDs) there was some
breakthrough in protection for animals receiving formulation
2, but full protection was seen in the mice immunized with
formulation 4 (Table 4). All untreated control animals rapidly
succumbed to infection, and the time to death was 2.8  0.2
days (mean  standard error of the mean). The calculated
retained dose of spores received by the mice challenged by the
aerosol route was 1.57 104 spores (equivalent to 30 MLDs by
this route). Immunization by any combination of administra-
tion routes with formulation 4a provided full protection against
aerosol challenge at this level. There was a single death in the
mice immunized with formulation 2a when i.n. priming and i.n.
TABLE 3. Immune responses of BALB/c mice (n  5) to either
two (formulations 2, 4, 5, and 6) or three (formulations 1 and
3) 10-g i.m. doses of rPA given as microencapsulated
formulations on days 1 and 21 (two-dose regimen)
and on days 1, 21, and 111 (three-dose regimen)
Formulation
Anti-rPA IgG titera
Day 28 Day 42 Day 85 Day 120
1 NDb 1.7 2.3 3.54 0.42
2 4.57  0.18 4.45  0.25 4.02  0.12 3.42  0.2
3 2.6 2.0 2.0 2.93 0.23
4 4.26  0.06 4.45  0.15 3.96  0.11 3.42  0.07
5 3.2  0.1 3.77  0.34 3.0  0.2 3.3  0.17
6 ND ND ND ND
a The titers are mean log10 reciprocal serum dilutions standard errors of the
means; single values are titers obtained from single responding animals. The
titers were determined on days 28, 42, 85, and 120 after the primary immuniza-
tion.
b ND, not detectable.
TABLE 2. Immune responses of A/J mice to three 10-g i.m. doses
of rPA given either free or in a microencapsulated formulation on
days 1, 28, and 63 and immune responses of A/J mice
given the human anthrax vaccine (one-fifth of
a human dose) on days 1, 28, and 42a
Treatment
Anti-rPA IgG titer
(g ml1)b No. of survivors/no.
challenged (%)c
Day 42 Day 84
Free rPA 169.31 1,044.79 6/6 (100)
Formulation 5 79.17 555.57 6/6 (100)
Anthrax vaccine 35.49 314.57 6/6 (100)
Naïve controls 0/6 (0)
a The mice were challenged on day 105 after the primary immunization.
b The values are mean anti-rPA IgG concentrations based on pooled samples
taken from six mice per treatment group on days 42 and 84 after the primary
immunization.
c Number of mice alive 14 days after challenge/number of mice challenged.
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boosting were used, but this formulation was fully protective
when it was administered by the i.m. route or by a combination
of i.m. and i.n. routes (Table 5). All untreated control animals
died, and the time to death was 3.4  0.5 days (mean 
standard error of the mean).
DISCUSSION
For optimum protection against pulmonary anthrax infec-
tion it is probably necessary for mucosal pathways, as well as
systemic immune pathways, to be primed. One way to achieve
good mucosal immunity in the lungs and respiratory tract is to
administer the antigen locally, in a particulate form. The pres-
ence of rPA as a particulate is critical for enhancing protective
immunity when it is administered i.n. In contrast, this study
showed that when delivered directly to the respiratory tract
epithelium of the mouse, rPA in aqueous solution is nonim-
munogenic unless it is combined with a mucosal adjuvant, such
as CTB.
Immunization studies with rPA incorporated into micro-
spheres and gel formers have been described previously (M.
Kende, C. Yan, J. Corbett, G. C. Atkins, and S. W. Shalaby,
Proc. Int. Symp. Controlled Rel. Bioactivated Mater. 2000,
abstr. 0223), and success with microencapsulation has previ-
ously been shown in mice with other antigens that protect, for
example, against Yersinia pestis infection (3). In this study it
was found that for two strains of mice, rPA can be encapsu-
lated in polymeric microparticles without impairment of the
immunogenicity and protective efficacy of the protein. In the
preliminary trial of the microencapsulated rPA formulation,
the circulating anti-rPA IgG concentrations in the formulation
5-immunized mice were approximately one-half those ob-
tained for the mice immunized with free rPA (Table 2). These
titers were greater than those in the human anthrax vaccine-
immunized mice, which received only one-fifth of a human
dose (approximately 0.5 g of PA, assuming an average vac-
cine PA content of 2.5 g per 0.5 ml [13]), 20 times less than
the dose of microencapsulated rPA delivered in formulation 5.
These data suggest that following i.m. injection, microencap-
sulated rPA is not processed and presented to the relevant
elements in the immune system as effectively as free antigen. It
is also feasible that exposure to sheer forces and/or organic
solvents during the manufacture of this formulation may have
damaged the critical antigenic epitopes of the rPA, reducing its
immunogenicity. A number of studies have shown that there is
no direct correlation between antibody titer to PA and protec-
tion against anthrax infection (12, 22, 25). Despite this, a cer-
tain threshold titer of antibody is most likely required for
protection, and although microencapsulated rPA formulation
5 was not as immunogenic as free rPA when it was adminis-
tered by the i.m. route, it induced the threshold titer necessary
FIG. 2. Anti-rPA IgG concentrations (means  standard errors of the means; n  5 for formulations 2 and 4; n  6 for formulations 2a and
4a) for A/J mice immunized with sufficient formulation 2, 4, 2a, or 4a to deliver a 10-g dose of rPA by either the i.m. route or the i.n. route on
days 1 and 21 of the immunization regimen. Samples were taken 28 days after the primary immunization.
TABLE 4. Survival of A/J mice immunized on two occasions (days
1 and 21) by the i.m. and i.n routes and challenged by the i.p.
route on day 55 with either 103 or 104 MLDs of STI spores
Treatment
group
Routes of
administration
No. of survivors/no.
challenged (%)
103 MLDsa 104 MLDs
Formulation 2 i.m.  i.m. 5/5 (100) 4/5 (80)
Formulation 2 i.n.  i.n. 5/5 (100) 3/5 (60)
Formulation 2 i.m.  i.n. 5/5 (100) 5/5 (100)
Formulation 2 i.n.  i.m. 5/5 (100) 5/5 (100)
Formulation 4 i.m.  i.m. 5/5 (100) 5/5 (100)
Formulation 4 i.n.  i.n. 5/5 (100) 5/5 (100)
Formulation 4 i.m.  i.n. 5/5 (100) 5/5 (100)
Formulation 4 i.n.  i.m. 5/5 (100) 5/5 (100)
Naïve control 0/5 (0) 0/5 (0)
a 1 MLD,  approximately 1  103 STI spores (1).
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for protection and produced a level of protection comparable
to that provided by the human anthrax vaccine.
Encapsulation and weak binding of antigen to biodegradable
polymers can act as a continuous antigen release system, po-
tentially reducing the number of immunizing doses required to
elicit a protective immune response. This is important for
patient compliance and also if there is a risk of exposure to the
pathogen soon after immunization. The original encapsulat-
ed rPA formulation tested, formulation 5, was protective af-
ter three immunizing doses of rPA-containing microspheres.
Compared to the number of doses recommended for the
United Kingdom vaccine (four doses over a 6-month period,
followed by yearly booster doses [human anthrax vaccine pack-
age insert]) or the United States vaccine (six doses over an
18-month period, followed by an annual booster dose [12]),
this is a substantial improvement, but the objective was to
reduce the number of doses more by further enhancing the
presentation of rPA to the immune effector cells.
In addition to microspheres containing entrapped rPA,
empty and rPA-containing particles with additional quantities
of surface-associated rPA were prepared and tested for immu-
nogenicity. It was anticipated that the immunogenicity of rPA
might be improved by association with microparticles and that
by using this method the potentially degradative elements that
might be encountered during microencapsulation could be
avoided. In the screening study, formulations 2 (rPA encapsu-
lated and weakly surface bound) and 4 (rPA weakly surface
bound to empty spheres) were found to be particularly prom-
ising. These formulations were used in an assessment of pro-
tective efficacy in the A/J mouse model and were found to
induce protection following only two immunizing doses. In A/J
mice there is a positive correlation between the immunizing
dose of rPA administered and the protective antibody response
stimulated, making this a suitable model for anthrax infection
studies (23, 25). Due to the relatively small size of a mouse, the
amount of spheres in a PBS suspension that can be adminis-
tered is limited, and this also limits the immunizing dose of
rPA delivered; however, with further modification of the mi-
croencapsulated formulations it may be possible to increase
the deliverable rPA dose and therefore reduce the number of
immunizing doses required to stimulate a protective immune
response still further in order to produce a single-dose vaccine.
In this study, we also assessed how the administration route
affected the immunogenicities and protective efficacies of for-
mulations 2 and 4, which were selected based on the screening
study, and the subsequently produced second batches of these
formulations (formulations 2a and 4a). For all four formula-
tions, i.m. priming followed by either i.m. or i.n. boosting
resulted in the highest anti-rPA titers, and all immunization
route combinations for formulations 2 and 4 protected against
an injected challenge with 103 MLDs of anthrax strain STI.
There was some breakthrough in protection of the mice im-
munized with formulation 2 (encapsulated and weakly surface-
bound rPA) at the higher injected-challenge level (104 MLDs).
Aerosol challenge of mice immunized with formulations 2a
and 4a gave results similar to the injected-challenge results; the
formulation 4a-immunized mice were fully protected against
challenge with 30 MLDs of STI spores, but some breakthrough
in protection was observed with the formulation 2a-immunized
mice. Despite this, mice that were immunized with any of the
four formulations by using a combined i.m.-i.n. schedule were
fully protected at all challenge levels against both injected and
aerosol challenges, which emphasized the importance of stim-
ulating both the mucosal and systemic immune systems to
obtain full protection against these types of challenges. It is
perhaps noteworthy that with the exception of the i.n. primed
groups, when formulations 4 and 4a were administered by
using the same regimen, they did not induce the same magni-
tude of antibody response. It is unlikely that the performance
of the different formulations could be attributed to their rPA
contents, since formulation 2 contained more rPA than formu-
lation 4 and indeed formulation 4a contained less rPA than
formulation 2a. It is more likely that release of rPA and the
accessibility of the rPA to the immune system are more critical
criteria for effective induction of protective immunity in re-
sponse to these formulations.
It has previously been demonstrated that immunization with
rPA results in a Th2-directed immune response (26). This was
also observed with rPA given as microspheric formulations,
independent of the route of administration, showing that there
is no qualitative difference in the antibody subclasses stimu-
lated. This indicates that the protective immune mechanisms
stimulated by the microsphere-associated rPA are identical to
the mechanisms stimulated by the administration of rPA with
other adjuvants, such as the alum used in the human anthrax
vaccine, although the specific protective immune mechanism
stimulated by PA immunization remains unknown.
This study demonstrated that association of rPA with bio-
degradable microparticles (either by entrapment or by surface
association or both) is an effective approach for immunization
against anthrax infection. Pharmaceutical modification of rPA
in this way appears to facilitate effective delivery of the antigen
to inductive sites in the mucosal immune system. We speculate
that the immunogenicity of rPA may be further enhanced due
to sustained release of the antigen from the polymeric carriers.
It is known that microspheric material enters nasally associated
lymphatic tissue, draining lymph nodes, and systemic immuno-
logical compartments following i.n. delivery. This may also
contribute to the effectiveness of microsphere-associated or
-entrapped rPA as a mucosal immunogen compared with the
effectiveness of soluble rPA. In this study the utility of com-
bined i.m. and i.n. immunization routes was particularly high-
TABLE 5. Survival 22 days after aerosol challenge of A/J mice (six
mice per group) immunized on days 1 and 21 by the i.m. and i.n.
routes with sufficient spheres of either formulation 2a or
formulation 4a to deliver a 10-g dose of rPA
Treatment
group
Routes of
administration
No. of survivors/no.
challenged (%)a
Formulation 2a i.m.  i.m. 6/6 (100)
Formulation 2a i.n.  i.n. 5/6 (83)
Formulation 2a i.m.  i.n. 6/6 (100)
Formulation 2a i.n.  i.m. 6/6 (100)
Formulation 4a i.m.  i.m. 6/6 (100)
Formulation 4a i.n.  i.n. 6/6 (100)
Formulation 4a i.m.  i.n. 6/6 (100)
Formulation 4a i.n.  i.m. 6/6 (100)
Naïve control 0/8 (0)
a The animals were challenged with 30 MLDs (1 MLD  approximately 500
STI spores).
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lighted. This approach could be adapted for human use if an
injected primary dose of microencapsulated rPA or rPA with
alum as an adjuvant were followed by a nasal booster dose of
microencapsulated antigen. This mixed-route regimen may be
particularly appropriate because the respiratory tract epithe-
lium is the initial site of infection following inhalation of an-
thrax spores, and it therefore seems logical to attempt to de-
velop vaccination strategies that evoke appropriate localized
responses to counteract the early events of pathogenesis. In
this study we confirmed that robust protection against both
injected and aerosol challenges with B. anthracis spores can be
achieved by utilizing these dual immune mechanisms.
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